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Abstract 
Background: Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. 
In this study, whole blood samples were analyzed for activation capacity and the activatability of CD4+ and CD8+ 
T-lymphocytes by human total myelin basic protein (MBP), human MBP 104–118 fragment, and guinea pig MBP 
68–82 fragment.
Methods: Whole blood samples from healthy human subjects were compared with samples from patients with 
multiple sclerosis (MS). In particular, the expression of CD69, a surface marker of T-lymphocyte activity, was measured 
via flow cytometry before and after 14 h of incubation with human total MBP, MBP 104–118 fragment and/or guinea 
pig MBP 68–82 fragment. The results were compared between 15 patients with MS and 15 healthy subjects.
Results: In response to all three MBP forms, CD4+ and CD8+ T-lymphocytes from patients with MS demonstrated 
greater activatability than those from healthy subjects. These results indicate that in patients with MS, latent pre-acti-
vation to MBP epitopes results in an increased activation capacity of T-lymphocytes.
Conclusion: This effect may occur because immunization against MBP (at least in a subset of patients) plays a patho-
physiological role in MS pathogenesis. Alternatively, this result may represent a non-specific, bystander autoimmune 
phenomenon.
© 2015 Arneth. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The symptoms of multiple sclerosis (MS) are considered 
to represent signs of an autoimmune disease [1]. In MS, 
the autoimmune response is directed against the enve-
lope and/or surface components of nerve sheaths (i.e., 
myelin sheaths, oligodendrocytes) [1–3].
MS is a human disease that is closely related to the 
animal model of experimental autoimmune encephalitis 
(EAE) [4]. In this animal model, mice are immunized by 
an injection of myelin basic protein (MBP) and subse-
quently develop an MS-like relapsing disease pattern.
However, whether immunization against MBP also occurs 
in humans as part of MS development is so far unknown [2, 
3]. Indeed, immunization against human MBP is associated 
with the occurrence of pre-activated T-lymphocytes specific 
to MBP, and several authors have described immune reac-
tions and autoimmune diseases as consequences of T-lym-
phocytes remaining from former immunizations [4–7].
To investigate this topic in greater detail, whole blood 
samples from patients with MS and healthy control sub-
jects were incubated with three different MBP types 
(human total MBP, human MBP 104–118 fragment, and 
guinea pig MBP 68–82 fragment) overnight. As a positive 
control, whole blood samples were preincubated with 
concanavalin A, and as a negative control, whole blood 
samples from the same subjects were preincubated with 
human albumin. Then, cells incubated with or without 
human MBP were examined by means of flow cytom-
etry, and the proportions of activated CD4+ and CD8+ 
T-lymphocytes from healthy control volunteers and 
patients with MS were evaluated.
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Methods
Patients
As part of routine blood tests, 15 patients with MS and 
15 healthy subjects underwent two withdrawals of EDTA 
whole blood in the morning (2 times, 7.5 ml each draw). 
Characteristics of the patients are given in Table  1. All 
patients provided informed consent. The study was 
approved by the relevant review board.
Lymphocyte activation
For each individual, the whole blood sample was typi-
cally divided into six 1  ml aliquots/tubes. Concanava-
lin A (Sigma-Aldrich, Bremen, Germany) was added 
to tube 1 (positive control). Tube 2 was left untreated. 
Tube 3 was treated with human albumin as a negative 
control. Human total MBP, human MBP 104–118 frag-
ment and guinea pig MBP (68–82 fragment, all Sigma-
Aldrich, Bremen, Germany) were added to tubes 4, 5 and 
6, respectively. All proteins were added to a final con-
centration of 2 µg/ml. All experiments (incubations and 
flow cytometric analysis) were performed in duplicate for 
each subject.
Incubation period
Incubation of the whole blood samples was performed 
with (tubes 4, 5, and 6) and without (tubes 2) the addition 
of MBP followed by flow cytometric analysis. All whole 
blood samples were incubated at 37 °C (98.6 °F) for 14 h. 
Approximately once every 2  h, the samples were gently 
mixed to keep the whole blood in motion.
Staining of cells for flow cytometry
A flow cytometric assay (Fastimmune) from Becton–
Dickinson (BD Bioscience, Heidelberg, Germany) was 
used. The following extracellular epitopes and/or mark-
ers were evaluated by flow cytometry: CD3, CD4, CD8, 
and CD69. Staining was performed after incubation 
according to the manufacturer’s instructions (FAST 
immune assay, Becton–Dickinson, San Diego, CA, USA). 
An antibody mixture (Becton–Dickinson, San Diego, 
CA, USA) was added to 50  µl of human whole blood. 
The antibody mixture contained antibodies against CD4, 
CD8, CD3, and CD69. CD3 is expressed predominantly 
by T-lymphocytes, CD69 is an early activation marker, 
CD4 is a marker for T-helper cells (CD4+ T-lympho-
cytes), and CD8 is a marker for cytotoxic T-lymphocytes 
(CD8+ T-lymphocytes). The antibody specific for CD69 
was labeled with R-phycoerythrin (PE), as PE is the most 
sensitive fluorochrome available for staining. The CD8−, 
CD3−, and CD4− specific antibodies were labeled with 
fluorescein isothiocyanate (FITC), peridinin chlorophyll 
protein (PerCP), and allophycocyanin (APC), respec-
tively. The blood samples were incubated with the anti-
body mixture for 20 min at room temperature.
Erythrocyte lysis
After a 20  min incubation period at room temperature 
with the antibody mixture, erythrocytes were lysed with 
450 µl of BD lysis buffer (1×) according to the manufac-
turer’s instructions (Becton–Dickinson). After 20 min in 
lysis buffer, the samples were analyzed by flow cytometry.
Flow cytometry
The samples were analyzed using a FACSCalibur (Bec-
ton–Dickinson, San Diego, CA) flow cytometer. The 
fluorescence values of FITC, PerCP, APC, and PE were 
measured and graphically overlaid. The cells were initially 
gated on the basis of the CD3 PerCP signal and side scat-
ter. The CD3-positive population was considered to be 
the T-lymphocyte population. A total of 30,000 events in 
the T-lymphocyte gate were recorded per sample.
Gating was performed based on side scatter and CD3 
expression for T-lymphocytes. Within this lymphocyte 
gate, CD4+ and CD8+ T-lymphocytes were separated 
on the x-axis. On the y-axis, the CD69 marker was plot-
ted versus the CD4 and CD8 markers to represent the 
T-lymphocyte activation markers on each of the dia-
grams. The proportions of activated CD4+ and CD8+ 
T-lymphocytes were determined as the percentage of 
double-positive CD4+/C69+ T-lymphocytes and/or 
as the proportion of double-positive CD8+/CD69+ 
T-lymphocytes.
Measurement evaluation
To evaluate the acquired data, the CD69 signal was com-
pared separately to the CD4 and CD8 signals. The CD69 
intensity was plotted against the CD4 and CD8 signals. 
The results were further analyzed with a four-field divi-
sion, which yielded double-positive cells (upper right, 
Table 1 Patient and healthy control subject characteristics
Demographic variables MS patients Healthy controls
Gender (men/women) 6/9 6/9
Age (years) 36.5 (6.0) 32 (5.5)
Years of education 13.0 (3.1) 13.0 (2.2)
Neurological assessment
 Disease duration (months) 32.2 (9.6) –
 Time since last relaps (months) 5.8 (6.5) –
 EDSS 0.92 (0.85) –
 Type of MS
 Relapsing remitting 13 –
 Primary progressive 2 –
 Secondary progressive – –
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UR), double-negative cells (lower left, LL), and cells 
in which only one of the markers was expressed (lower 
right, LR and upper left, UL). Therefore, the percentage of 
activated T-lymphocytes in each subpopulation (CD4+ 
or CD8+) was determined. The percentage of activated 
cells corresponded to the quotient of double-positive 
cells (UR) divided by the sum of the single-positive cells 
and the double-positive lymphocytes for each population 
(UR + LR). Thus, the quotients q4 and q8 were calculated 
for both CD4+ and CD8+ T-lymphocytes as follows 
q = UR/(UR + LR).
Statistical analysis and normalization for baseline 
activation
The untreated blood samples consistently displayed a few 
weakly activated T-lymphocytes. To account for these 
cells in each experiment, the difference between the quo-
tients of the treated and untreated blood samples from 
each subject were calculated. These differences were 
termed Δq4  =  q4  −  q40 and Δq8  =  q8  −  q80 for the 
CD4+ and CD8+ lymphocytes, respectively. Thus, the 
values obtained for q4 and q8 represented the percent-
ages of activated T-lymphocytes in a treated sample (q4, 
q8) after the subtraction of background activation (q40, 
q80).
To investigate the influence of MBP in a mathematical/
statistical way, the proportions of activated CD4+ and/or 
CD8+ T-lymphocytes from samples incubated with and 
without MBP were compared using Student’s t test and 
the Wilcoxon test.
In addition, the mathematical differences in activated 
T-lymphocytes were calculated for incubation with and 
without the specific peptide added (Δq4, Δq8).
Results
Figure 1 illustrates the differences between Δq4 (Fig. 1a) 
and Δq8 (Fig. 1b).
Figure  1a shows the differences in CD4+ T-lympho-
cyte activation between patients with MS (MS multiple 
sclerosis) and healthy control subjects (HC healthy con-
trols); the numbers of activated CD4+ T-lymphocytes in 
samples incubated with and without the different MBPs 
(Δq4) are shown. Figure 1b shows the differences in Δq8 
(CD8+) T-lymphocyte activation between patients with 
MS and healthy subjects (analogous to Fig. 1a, * statistical 
significant increase p < 0.01).
The samples from healthy subjects demonstrated up to 
2  % more activated T-lymphocytes following the differ-
ent MBP overnight incubations. However, the samples 
from patients with MS clearly demonstrated many more 
activated T-lymphocytes; these patient samples showed 
up to 10 % (mean 7 %) more activated CD4+ and CD8+ 
T-lymphocytes following overnight MBP incubation. 
There was no significant difference between the numbers 
of activated CD4+ and/or CD8+ T-lymphocytes.
Duplicate samples from the same subject always 
showed a high degree of consensus (always  <2  % 
difference).
Figure  2a and b present the percent changes in the 
number of activated T-lymphocytes following over-
night incubation with and without the different MBPs 
for CD4+ (Fig. 2a) and CD8+ (Fig. 2b) T-lymphocytes. 
H-without indicates healthy subjects and incubation 
without MBP. H-with indicates healthy subjects and 
Fig. 1 Activated cell populations of CD4+ T-cells Δq4 (a) and/or 
of activated CD8+ T-cells Δq8 (b) between the MBP-treated and 
the respective untreated samples. Significantly more activated 
T-lymphocytes were observed in samples from MS patients follow-
ing an overnight incubation with MBP compared to samples from 
healthy controls (HCs). The effect was stronger for human total MBP 
than for human MBP 104–118 fragment an than fot guinea pig MBP 
68–82 fragment. HC-ConA/HC-Alb/HC-huMBP/HC-huMBP114/
HC-gpMBP68–82: Blood from HC incubated with concanavalin A, 
human albumin, human total MBP, huMBP104–118 peptide and/or 
guinea pig MBP 68–82 peptide. MS-ConA/MS-Alb/MS-huMBP/MS-
huMBP114/MS-gpMBP68–82: blood from MS patients incubated with 
concanavalin A, human albumin, human MBP, human MBP104–118 
peptide and/or guinea pig MBP 68–82 peptide (*significantly differ-
ent, p < 0.01)
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incubation with MBPs (human total MBP, MBP 104–118 
fragment, and/or guinea pig MBP 68–82 fragment). MS-
without indicates MS-patients and incubation without 
any MBP. Finally, MS-with indicates MS-patients and 
incubation with the different MBPs (human total MBP, 
MBP 104–118 fragment, and/or guinea pig MBP 68–82 
fragment).
In samples from healthy subjects, there were small 
increases in the numbers of both activated CD4+ lym-
phocytes and activated CD8+ T-lymphocytes. Com-
pared to this small to moderate increase, there was a 
much stronger increase in the numbers of activated 
CD4+ and CD8+ T-lymphocytes following overnight 
MBP incubation in whole blood samples from patients 
with MS. For all three tested MBPs, this increase in acti-
vated CD4+ and CD8+ T-lymphocytes was statistically 
significant (p < 0.01). However, this increase in activated 
T-cells was most prominent following incubation with 
human total MBP, followed by human 104–118 fragment; 
the smallest increase was observed following incuba-
tion with guinea pig MBP 68–82 fragment (human total 
MBP > huMBP-104–118 > gpMBP-68–82).
Discussion
Prior to MBP stimulation, blood samples from patients 
with MS exhibited only a slightly higher amount (2  %) 
of CD69+ T-lymphocytes compared with those from 
healthy subjects. This effect was not detectable in sam-
ples from all patients.
In contrast, the percentage of CD69+ T-lymphocytes 
was increased following MBP stimulation in samples 
from almost all patients with MS. The effect was stronger 
if total human MBP was used compared to either human 
MBP 104–118 fragment or guinea pig MBP 68–82 
fragment.
In blood samples from healthy individuals, the effect of 
MBP stimulation on the proportion of activated T-lym-
phocytes was lower and was not detectable in the sam-
ples from a majority of subjects.
The results presented here demonstrate that T-lym-
phocytes from patients with MS respond very differently 
to MBP compared with T-lymphocytes from healthy 
subjects.
While the T-lymphocytes from healthy subjects dem-
onstrated a relatively small response to MBP (or even 
no response), the reaction was significantly stronger in 
T-lymphocytes from patients with MS.
If we assume that the T-lymphocyte response is sig-
nificantly stronger following the second contact with the 
same antigen or epitope (see Stryer, Janeway, and Kuby) 
[1, 8, 9], the results of this study suggest that previous 
contact with MBP may contribute to the development of 
MS in vivo.
Our results suggest that, at least in a subset of patients 
with MS, there is latent pre-activation of CD4+ and 
CD8+ T-lymphocytes towards MBP epitopes. Moreover, 
these findings are in agreement with the current opinion 
regarding MS pathogenesis [10–15].
Conclusion
Pre-activation of CD4+ and CD8+ T-lymphocytes to 
MBP seems to be present in several MS patients. Fur-
thermore, our results demonstrate that MBP is a major 
auto-antigen in patients with MS.
Fig. 2 The percentages of activated CD4+ T-lymphocytes (a) and/or 
CD8+ T-lymphocytes (b) among treated and untreated cell aliquots. 
A significant increase in the number of activated T-lymphocytes was 
observed in the whole blood from patients with MS compared to in 
whole blood from healthy subjects following an overnight incubation 
with MBP. In comparison, samples from healthy subjects exhibited 
significantly fewer activated T-lymphocytes following incubation with 
the different MBPs. (*significantly different, p < 0.01). HC-without: 
blood from healthy controls (HC) without proteins/peptides added; 
MS-without: blood from MS patients without proteins/peptides 
added. HC-with total huMBP, huMBP104–1184, gpMBP68–82: blood 
from HC incubated with human MBP, human MBP104–118 peptide 
and/or guinea pig MBP 68–82. MS-with total huMBP, huMBP104–118, 
gpMBP68–82: blood from MS patients incubated with human MBP, 
human MBP104–118 peptide and/or guinea pig MBP 68–82
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However, it remains unclear whether this result is 
a pathogenically relevant step in MS development or 
whether it is a non-specific secondary reaction.
The autoimmune response to MBP as an auto-antigen 
may constitute a pathogenetically significant immune 
response against an endogenous auto-antigen [2, 3]. In 
addition, this phenomenon may also be non-specific and 
driven via a bystander autoimmune response.
However, the evidence points toward the former 
hypothesis and is strengthened by the similarities 
between MS and the EAE animal model. In this model, 
MBP immunization is a required step for EAE develop-
ment, and EAE is currently the best animal model of 
human MS disease [4].
It is also possible that MBP stimulates a non-specific, 
bystander autoimmune response, as pre-activation of 
T-lymphocytes against MBP was not detectable in all 
patients with MS. Thus, this relevant question cannot be 
fully answered in this context.
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